FMP
MoonLake Immunotherapeutics
MLTX
NASDAQ
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
42.19 USD
-0.06 (-0.142%)
About
ceo
Dr. Jorge Santos da Silva
sector
Healthcare
industry
Biotechnology
website
https://www.moonlaketx.com
exchange
NASDAQ
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
CIK
0001821586
ISIN
KY61559X1045
CUSIP
61559X104
Address
Dorfstrasse 29
Phone
41 415108022
Country
CH
Employee
50
IPO Date
Oct 20, 2020
Summary
CIK
0001821586
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
61559X104
ISIN
KY61559X1045
Country
CH
Price
42.19
Beta
1.19
Volume Avg.
476.38k
Market Cap
2.63B
Shares
-
52-Week
19.8-64.98
DCF
9.11
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-57.79
P/B
-
Website
https://www.moonlaketx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MLTX News
It looks like there's no news available.
